Volume 28, Issue 1 - Careers in medical writing

Clinical trial disclosure landscape and awareness in Japan

Authors: Hiroko Ebina, Jocelyn Colquhoun

Abstract

Download the full article

References

1. The Government of Japan. Act on access to information held by administrative organs. Act No. 42. 1999 May 14 [cited 2019 Jan 18]. Available from: http://elaws.e-gov. go.jp/search/elawsSearch/elaws_search/ lsg0500/detail?lawId=411AC0000000042. Japanese
2. Procedural guidance for administrative processing related to access to information held by the Pharmaceutical and Food Safety Bureau. PFSB Notification No. 0330022 from the Director General of the Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. 2007 Mar 30 [cited 2019 Jan 18]. Available from: https://www.pmda.go.jp/review-services/drug-reviews/review-information/p-drugs/0020.html
3. Procedures for public release of information on review of applications for new drug. PMDA Notification No. 0325004 from the Chief Executive of the Pharmaceuticals and Medical Devices Agency. 2013 March 25 [cited 2019 Jan 18]. Available from: https://www.pmda.go.jp/files/000204879. pdf. Japanese.
4. Viergever RF, Li K. Trends in global clinical trial registration: an analysis of numbers of registered clinical trials in different parts of the world from 2004 to 2013. BMJ Open. 2015;5(9):e008932.
5. Ministry of Health, Labour and Welfare. Ethical guidelines for clinical research in Japan. Notification No. 0731001 from the Director of the Health Bureau, Ministry of Health, Labour and Welfare. Revised 2008 Jul 31 [cited 2019 Jan 18]. Available from: https://www.mhlw.go.jp/general/seido/ kousei/i-kenkyu/rinsyo/dl/shishin.pdf. Japanese.
6. Ministry of Health, Labour and Welfare, Ministry of Education, Culture, Sports, Science and Technology. Ethical guidelines for medical and health research involving human subject. Notification No. 0228-1 from Director of Health Bureau, Ministry of Health, Labour and Welfare, Notification No. 28-406 from the Director General of the Research Promotion Bureau, Ministry of Education, Culture, Sports, Science and Technology. Revised 2017 Feb 28 [cited 2019 Jan 18]. Available from: https://www.mhlw.go.jp/file/06- Seisakujouhou-10600000- Daijinkanboukouseikagakuka/0000153339 .pdf. Japanese.
7. Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, et al. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ. 2016;352:i637.
8. Tang W, Fukuzawa M, Ishikawa H, Tsutani K, Kiuchi T. Review of the registration of clinical trials in UMIN-CTR from 2 June 2005 to 1 June 2010 - focus on Japan domestic, academic clinical trials. Trials. 2013;14:333.
9. Ochi N, Kawahara T, Nagasaki Y, Nakagawa N, Yamagishi T, Umemura S, et al. Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry. Jpn J Clin Oncol. 2018;48(11):995–1000.
10. Ministry of Health, Labour and Welfare. Format for preparing the common technical document for submission of new drug applications to reduce total review time. Administrative notice from the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. 2011 Jan 17 [cited 2019 Jan 18]. Available from: https://www.pmda.go.jp/files/000209183. pdf. Japanese.
11. Hamilton S, Bernstein AB, Blakey G, Fagan V, Farrow T, Jordan D, et al. Developing the Clarity and Openness in Reporting: E3-based (CORE) Reference user manual for creation of clinical study reports in the era of clinical trial transparency. Res Integr Peer Rev. 2016;1(1):4.
12. Ebina H, Fagan V, Gertel A. Driving international awareness and use of regulatory writing guidelines: case studies of the Clarity and Openness in Reporting (CORE) Reference guidelines. Drug Information Association (DIA) 2017 Global Annual Meeting, Chicago, July 18–22, 2017 (presentation).